Profil
Mr. Isaac Stoner is a Chief Executive Officer & Director at Mindimmune Therapeutics, Inc. He is on the Board of Directors at Mindimmune Therapeutics, Inc. Mr. Stoner was previously employed as a President, Chief Executive Officer & Director by Octagon Therapeutics, Inc. He received his undergraduate degree from Brown University and an MBA from MIT Sloan School of Management.
Aktive Positionen von Isaac Stoner
| Unternehmen | Position | Beginn |
|---|---|---|
Mindimmune Therapeutics, Inc.
Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs that target immune system for treating diseases related to central nervous system | Vorstandsvorsitzender | 24.11.2025 |
Ehemalige bekannte Positionen von Isaac Stoner
| Unternehmen | Position | Ende |
|---|---|---|
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotics and medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells | Vorstandsvorsitzender | 02.01.2025 |
Ausbildung von Isaac Stoner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIT Sloan School of Management
MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mindimmune Therapeutics, Inc.
Mindimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs that target immune system for treating diseases related to central nervous system | Health Technology |
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Develops antibiotics and medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells | Health Technology |
















